April 17 (Reuters) - The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
Pre-market 07:01:18 | |||
775 USD | -0.36% | 777.1 | +0.27% |
05-08 | China Merchants Initiates Eli Lilly at Buy Rating With $852 Price Target | MT |
05-07 | Coca Cola's new bond prices tight, investors still hungry for new debt | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+16.09% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B | |
-1.81% | 160B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says